近日,在南亞等地出現(xiàn)了一種超級(jí)病菌。據(jù)報(bào)道,這種新型病菌可以通過飲水等途徑傳播,引發(fā)腸道感染等病癥,而且對(duì)幾乎所有抗生素都具有抗藥性。英國醫(yī)學(xué)周刊日前發(fā)布研究報(bào)告稱,這種病菌發(fā)源于印度,并用印度首都新德里為前綴為該病菌命名。印度政府對(duì)此表示憤怒,宣稱這是針對(duì)該國正在起步的醫(yī)療旅游業(yè)的陰謀。印度衛(wèi)生部在一份聲明中說,西方一些媒體僅根據(jù)不完整的病例報(bào)告就把這種不明原因的病菌與印度聯(lián)系起來,這是非常錯(cuò)誤和不公正的。印度尤其反對(duì)用印度首都新德里的名字來命名這種病菌。聲明說,印度的醫(yī)療機(jī)構(gòu)一向?yàn)榍皝碛《冗M(jìn)行醫(yī)療旅游的外國游客提供良好的治療和護(hù)理?xiàng)l件,目前印度完全沒有受到這種新出現(xiàn)的病菌的威脅,在印度旅行以及在印度的醫(yī)院進(jìn)行治療都是絕對(duì)安全的。
Superbug: India denies that it is to blame for the new strain. (Agencies) |
India has reacted angrily to a medical study linking Indian hospitals to a multi-resistant "superbug," with some politicians claiming a conspiracy against the country's booming medical tourism industry.
The study, published in the British medical journal The Lancet, said health tourists flocking to South Asia had carried a new class of antibiotic-resistant superbug to Britain, and warned that it could spread worldwide.
In a strong statement issued late Thursday, the Indian health ministry criticized the report for scaremongering and took particular exception to the naming of the NDM-1 bacteria -- or "New Delhi metallo-lactamase-1".
The ministry acknowledged that such bacteria might circulate more widely with advances in international travel.
"But to link this with the safety of surgery in hospitals in India and citing isolated examples to show that... India is not a safe place to visit, is wrong," the statement said.
"We strongly refute the naming of the enzyme... and also refute that hospitals in India are not safe for treatment including medical tourism."
The NDM-1 gene was first identified last year by Cardiff University's Timothy Walsh in two types of bacteria -- Klebsiella pneumoniae and Escherichia coli -- in a Swedish patient admitted to hospital in India.
Worryingly, the new NDM-1-carrying bacteria are resistant even to carbapenems, a group of antibiotics often reserved as a last resort for emergency treatment for multi-drug resistant bugs.
Researchers said the bugs had been brought into Britain by patients who travelled to India or Pakistan for cosmetic surgery.
South Asia, and India in particular, is undergoing a medical tourism boom, with swanky new hospitals and well-trained medical staff offering everything from facelifts to fertility treatments and open-heart surgery at half the price of western Europe.
The Lancet study was mentioned in India's parliament with some angry MPs denouncing what they saw as a plot by global pharmaceutical firms.
"When India is emerging as a medical tourism destination, this type of news is unfortunate and may be a sinister design of multi-national companies," said Hindu-nationalist MP SS Ahluwalia.
India has been criticized in the past for having a loose policy on antibiotics use, with the result that they are over-prescribed and over-used to the point where resistant strains become more common.
V.M. Katoch, director general of the Indian Council of Medical Research, told AFP that multiple drug resistance was "always a concern".
"But when you draw conclusions that link it to a specific country, then you are going too far," Katoch said.
"When you link it to our antibiotics policy... say it is dangerous to get operated on in India and that you will get more infections, that is totally irrational."
In the new study, led by Walsh and Chennai University's Karthikeyan Kumarasamy, researchers set out to determine how common the NDM-1-carrying bacteria were in South Asia and Britain, where several cases had turned up.
Checking hospital patients with suspected symptoms, they found 44 cases -- 1.5 percent of those screened -- in Chennai, and 26 (eight percent of those screened) in Haryana, both in India.
They likewise found the superbug in Bangladesh and Pakistan, as well as 37 cases in Britain, some in patients who had recently returned from having cosmetic surgery in India or Pakistan
Anil Chadha, a senior plastic surgeon in the west Indian city of Ahmedabad, said the way the study had been reported in the media was bound to scare off some foreigners.
"People will think twice before coming to India for a treatment. I think the reports are economically motivated to prevent patients coming here," Chadha told AFP.
Another plastic surgeon, K.M Kapoor, based in the northern city of Mohali, agreed that the study was being used to "malign" India's health system.
"And naming the bug after New Delhi is simply ridiculous," he added.
相關(guān)閱讀
(Agencies)
(中國日?qǐng)?bào)網(wǎng)英語點(diǎn)津 Helen 編輯)